Ilixadencel - Immunicum

Drug Profile

Ilixadencel - Immunicum

Alternative Names: Allogeneic cancer vaccine - Immunicum; COMBIG-DC; Dendritic cell vaccine - Immunicum; INTUVAX-GIST; INTUVAX-HCC; INTUVAX-RCC

Latest Information Update: 22 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Immunicum
  • Developer Immunicum; Uppsala University
  • Class Cancer vaccines; Dendritic cell vaccines
  • Mechanism of Action CD8 positive T lymphocyte stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Renal cell carcinoma
  • Phase I Gastrointestinal stromal tumours
  • No development reported Hepatocellular carcinoma

Most Recent Events

  • 20 Mar 2018 The EMA issues advanced therapy medicinal product certificate for manufacturing quality and non-clinical data for ilixadencel
  • 08 Jan 2018 Immunicum completes enrolment in its phase II MERECA trial for Renal cell carcinoma (Metastatic disease, Combination therapy) in Sweden (Intratumoural) (NCT02432846)
  • 29 Dec 2017 Immunicum plans a clinical trial for Cancer (Combination therapy)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top